Citi Pharma Limited: performance and outlook

Business Recorder reported on the performance of Citi Pharma Limited (CPHL), a pharmaceutical maker listed on the Pakistan Stock Exchange since 2021. Over the first nine months of the current fiscal year, the company's net sales climbed 6.81 percent to Rs10,787.56 million, helped by stronger demand, a wider product range, price revisions and a richer mix of formulation products. Gross profit rose 37.27 percent, with gross margin reaching 18.53 percent compared with 14.42 percent in 9MFY25.

Net profit increased 30.14 percent to Rs883.44 million, with earnings per share of Rs3.87 against Rs2.97 a year earlier, and the net margin widened from 6.72 percent to 8.19 percent. Finance costs, however, rose 21.83 percent on higher outstanding liabilities, while administrative costs grew 2.50 percent and distribution costs 49 percent. Other income fell 52.15 percent, attributed to thinner short-term investments and monetary easing.

Business Recorder also noted that CPHL has recently begun exporting finished nutraceuticals to the US market after FDA approval. The company has also formed a joint venture with Hangzhou Newsea Technology Co Ltd to develop new APIs. On May 06, 2026, it announced approval of a plan to acquire a 100 percent stake in Pakheim International Pharmaceuticals (Private) Limited.